Founded
2017
Founder & CEO
Andreas Katapodis
% Shareholding
51%
Stage
Clinical
Number of employees
10+
Raised in a Series A financing in February 2019
CHF35m

Unless stated all financials at 30 June 2021

Anaveon website

Anaveon is a pre-clinical phase biopharmaceutical company that specialises in the development of treatments for diseases with immune system dysfunction.

Anaveon is a pre-clinical phase biopharmaceutical company that develops biologics to modulate the function of cytokines with the potential to provide substantial therapeutic benefit to cancer patients.  Its vision is to develop novel immune therapies benefiting patients suffering from a wide variety of diseases with immune pathology.

Anaveon is developing selective IL-2 Receptor agonists, which have the potential to therapeutically enhance a patient’s immune system to respond to tumours. In the body, human IL-2 stimulates a type of immune cell, called a T-cell, to multiply and become activated.  Activated T-cells are able to attack tumours and, consistent with this approach, human IL-2 is already approved as a therapeutic for the treatment of metastatic melanoma and renal cancer; however  human IL-2 has severe, dose-limiting side effects due to lack of specificity and a short half-life that requires frequent infusions. Anaveon’s lead compound, ANV419, is designed to preferentially signal through the IL-2 beta/gamma receptor and therefore overcome known challenges of human IL-2. This novel type of therapeutic, if approved, could potentially have a wide utility in oncology, including in combination with a wide range of modalities such as cell therapies, vaccines, checkpoint inhibitors and radiotherapy.

Investment opportunity

  • Developing a selective IL-2 agonist with improved administration and toxicity burden
  • Wide potential utility across multiple oncology indications in wider markets*

Unmet medical need

  • Human IL-2 approved as a medicine for the treatment of metastatic melanoma and renal cancer, but with a cumbersome administration schedule and significant toxicity**

Key risks

  • Multiple players and highly competitive
  • Strategy for differentiation and clinical/commercial positioning
  • Clinical risk

 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4938354/

** https://www.cancernetwork.com/view/managing-toxicities-high-dose-interleukin-2 

The Anaveon pipeline

Research Pre-clinical Clinical
  • ANV419

Syncona team

Martin Murphy

Martin Murphy

Martin is Chief Executive Officer of Syncona Investment Management Ltd. He co-founded Syncona in 2012 alongside The Wellcome Trust. Since then, Martin has been closely involved in the foundation and development of seven Syncona companies, including: Achilles Therapeutics, Autolus, OMass Therapeutics, Quell Therapeutics, Anaveon and Resolution Therapeutics. He is Chairman of Quell and Anaveon and i…
View Martin's biography
Position
Chair
Qualification
PhD
Alice Renard

Alice Renard

Alice is a Partner of Syncona Investment Management Ltd. She is also currently Head of Operations at Purespring Therapeutics and works closely with Anaveon. Alice serves as an Observer on the Board of Purespring and Anaveon. Prior to joining Syncona, Alice was an Investment Banking Analyst within Barclays’ Healthcare Corporate Finance and M&A team, where she worked on transactions involving ph…
View Alice's biography
Position
Board observer
Qualification
PhD
Dominic Schmidt

Dominic Schmidt

Dominic is a Partner of Syncona Investment Management Ltd. He is a a Director on the board of Anaveon, and Purespring Therapeutics. Prior to joining Syncona, Dominic worked in the life science practice of strategy consultancy L.E.K Consulting. He received his PhD from the Department of Oncology at the University of Cambridge where he was a Cancer Research UK scholar. He also holds a German Diplom…
View Dominic's biography
Position
Board member
Qualification
PhD

Anaveon leaders and founders

Anaveon publications & presentations

Show presentations from

Anaveon Corporate Presentation

Download PDF (1.54Mb)